• 1
    Ceriani R, Peterson J, Lee J, Moncada R, Blank EW. Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule. Somat Cell Genet 1983; 9: 41527.
  • 2
    Ceriani R, Blank E, Couto J, Peterson J. Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms. Cancer Res. 1995; 55(Suppl 23):5852s5865s.
  • 3
    Couto J, Christian R, Peterson J, Ceriani R. Designing human consensus antibodies with minimal positional templates. Cancer Res 1995; 55(Suppl 23): 5973s5977s.
  • 4
    Abdel-Nabi H, Spaulding M, Goldroken M, Bakshi S, Foon KA, Evans N, et al. Phase I trial of IP admininstered 90Y labeled CYT-103 MoAb for refractory colorectal carcinomas [abstract]. J Nucl Med 1991; 32: 1052.
  • 5
    Jurcic JG, Divgi CR, McDevitt MR, Ma D, Sgouros G, Hamacher KA, Finn RD, Larson SM, and Scheinberg DA. Phase I trial of Yttrium-90-HuM195 (Anti-CD33) in myeloid leukemia: potential for myeloablation. Cancer Biother Radiopharm 2000;15:408.
  • 6
    Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, et al. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 1998; 4: 167988.
  • 7
    DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a Phase I clinical trial. J Nucl Med 1997; 38: 11805.
  • 8
    Johnson TK, McClure DL, McCourt SL. MABDOSE. I. Characterization of a general purpose dose estimation code. Med Phys 1999;26: 138995.
  • 9
    Johnson TK, McClure DL, and McCourt SL. MABDOSE. II. Validation of a general purpose dose estimation code. Med Phys 1999;26: 13961403.